Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. New England Journal of Medicine 2023;389:2221-2232.
What it found
In adults aged 45 or over with existing cardiovascular disease, overweight or obesity and no diabetes, cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80). Side effects led to stopping the drug in 16.6% vs 8.2%.
Limitations
Only people with established heart or vessel disease; results do not apply directly to people with obesity but no cardiovascular disease. Absolute difference in events was about 1.5 percentage points over more than 3 years.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.